A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Study ID

Protocol Number: 22-2098

More information available at ClinicalTrials.gov: NCT04494256

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers